Skip to content
The Policy VaultThe Policy Vault

Cometriq (cabozantinib) — CareFirst (Caremark)

Medullary thyroid carcinoma

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months